From: A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy
Aberrancy
CD3
CD4
CD5*
CD7
CD8
CD26
CD45*
TCR*
% of cases
34%
54%
25%
61%
5%
86%
40%
31%
cases tested
15/44
24/44
5/20
27/44
2/44
38/44
4/10
6/19